Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120351) titled 'Efficacy and Safety Analysis of Ajamod versus Immunoglobulin G in Rescuing Patients from Myasthenia Gravis Crisis' on March 12.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: General Hospital of Ningxia Medical University
Condition:
Myasthenia gravis
Intervention:
Efgartigimod Group:Efgartigimod 10 mg/kg IV every 1 week for 4 consecutive weeks, with an interval of 2 to 4 weeks between courses.
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2024-03-07
Target Sample Size: Efgartigimod Group:30;Ig Group:30;
Countries of Recruitment:
China
To know more,...